Osteogenesis Imperfecta — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Adipose-derived mesenchymal stem cells-derived exosomes containing nano-pearl powder water-soluble matrix promote osteogenic differentiation of MC3T3-E1 cells.
Chen Ling et al. — Organogenesis (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41746760/
- 2.
Integrated targeted metabolomics and transcriptomics analysis reveals heterogeneity of subcutaneous and pericardial adipose tissues in Yili horses.
Yang Liping et al. — Food chemistry. Molecular sciences (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41660677/
- 3.
Sinominine alleviates pulmonary fibrosis by suppressing macrophage-to-myofibroblast transition via inhibition of the Frem1/NF-κB/IL-1β axis.
Zheng Junhui et al. — International immunopharmacology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41833105/
- 4.
A radiological case series of three siblings with osteogenesis imperfecta and shared paternal inheritance.
Nelwan Dario Agustinus et al. — Radiology case reports (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41717638/
- 5.
Salvianolic acid C attenuates liver fibrosis and inhibites hepatic stellate cell activation by targeting FAP/TβRI/SMAD axis.
Sun Tao et al. — International immunopharmacology (15 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41740338/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Recruiting — Phase 3 — Dimerix Bioscience Pty Ltd
https://clinicaltrials.gov/study/NCT05183646
- 2.
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Recruiting — Phase 3 — Amgen
https://clinicaltrials.gov/study/NCT07213674
- 3.
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Recruiting — Phase 3 — Amgen
https://clinicaltrials.gov/study/NCT05972551
- 4.
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Recruiting — University of Michigan
https://clinicaltrials.gov/study/NCT05388708
- 5.
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Recruiting — Phase 2 — Angitia Incorporated Limited
https://clinicaltrials.gov/study/NCT07062588
- 6.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting — Phase 3 — Ipsen
https://clinicaltrials.gov/study/NCT06016842
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Osteogenesis Imperfecta
Osteogenesis imperfecta (brittle bone disease) is a group of genetic conditions causing fragile bones that fracture easily. Most cases are caused by mutations in collagen genes. Severity ranges from mild to severe. Bisphosphonate therapy strengthens bones, and new treatments including gene-based approaches are in trials.
Most Recent Research
OBJECTIVE: To explore the synergistic effect of nano-pearl powder (NPP) and adipose-derived stem cell exosomes (ADSC-Exos) on the osteogenic potential of MC3T3-E1 cells. METHODS: The water-soluble matrix of NPP (NPP-WSM) was extracted via freeze-drying, and ADSC-Exos were isolated by ultracentrifugation. NPP-WSM was incorporated into ADSC-Exos through co-incubation to generate NPP-WSM-Exos. MC3T3-E1 cells were treated with NPP-WSM or NPP-WSM-Exos. Cell proliferation and migration were evaluated using CCK-8 and wound-healing assays, respectively. Osteogenic differentiation was assessed by Alizarin Red S staining and alkaline phosphatase (ALP) activity. The expression of osteogenesis-related genes (COL1A1, RUNX2, OCN, and OPN) was measured by qPCR and Western blotting. Transcriptome sequencing (RNA-seq) was conducted to identify signaling pathways activated by NPP-WSM-Exos. RESULTS: NPP-WSM-Exos displayed distinct exosome morphology and biomarkers, confirming their successful preparation. Significantly, NPP-WSM-Exos enhanced the viability of MC3T3-E1 cells compared to NPP-WSM alone and upregulated the expression of osteogenic genes, including COL1A1, RUNX2, OCN, and OPN, at both the transcriptional and translational levels. Additionally, NPP-WSM-Exos strongly promoted mineralization, as evidenced by the increased calcification observed through Alizarin Red S staining, and elevated alkaline phosphatase (ALP) activity, indicating excellent potential for osteogenic differentiation. Transcriptome sequencing showed that NPP-WSM-Exos significantly enhanced the PI3K/AKT pathway in MC3T3-E1 cells, while protein level detection indicated that NPP-WSM-Exos could increase AKT phosphorylation levels and inhibit GSK3β activity to improve osteogenic efficiency. CONCLUSION: The use of adipose-derived stem cell exosomes to encapsulate NPP-WSM can increase the utilization of WSM, promote the proliferation of MC3T3-E1, and enhance the osteogenic differentiation ability.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.